BBIO | tickerfilter.com

Fundamental analysis

30%

Profitability 15%

Dept financing 25%

Liquidity 58%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.05%

1 Month

1.45%

3 Months

8.94%

6 Months

12.79%

1 Year

9.09%

2 Year

117.27%

Key data

Stock price

$31.57

P/E Ratio

0.00

DAY RANGE

$31.22 - $32.64

EPS

-$2.88

52 WEEK RANGE

$21.62 - $39.47

52 WEEK CHANGE

$10.00

MARKET CAP

5.186 B

YIELD

N/A

SHARES OUTSTANDING

188.033 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.09

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,534,803

AVERAGE 30 VOLUME

$3,649,588

Company detail

CEO: Neil Kumar
Region: US
Website: bridgebio.com
Employees: 400
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.

BBIO - BridgeBio Pharma, Inc.